CLVS earnings

First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowest (3.7 GBq) dose cohort Recruitment of third of four planned dose cohorts is ongoing Initiation of Phase 2 expansion cohorts in multiple tumor types anticipated in Q4 2022 Phase 3 ATHENA trial evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in front-line maintenance treatment of ovarian cancer presented at 2022 ASCO Annual Meeting Simultaneous publication in the Journal of Clinical Oncology (JCO) Presented at

Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days. Dial-in numbers for the conference call are as follows: US participants 888.440.4615 International participants 646.

ATHENA study evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in first-line ovarian cancer maintenance treatment successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Median PFS of 20.2 months for Rubraca vs 9.2 months for placebo in ITT population Late-breaker data to be presented in oral session at 2022 ASCO Annual Meeting on Monday, June 6 Two additional top-line Phase 3 data read-outs for Rubraca expected in next 12 months with potential to address ovarian and prostate cancer patient populations Initial Phase 1 clinical data for targeted radiothera

Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company's results in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days. Dial-in numbers for the conference call are as follows: US participants 888.440.4615, International participants 646.960.0682, conference ID: 2259685. About Clovis Oncology Clovis Oncology, Inc. is a biopharmaceutical company

ATHENA study evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Median PFS of 20.2 months for Rubraca vs 9.2 months for placebo in the ITT population The exploratory PFS endpoints were also achieved in both HRD-negative and BRCA mutant subgroups of patients Safety of Rubraca observed in ATHENA-MONO was consistent with both the current US and European labels ATHENA-MONO results will serve as the basis of a supplemental NDA for US label expansion to be submitted during Q2 2022; European submission to follow during Q

Three top-line Phase 3 data read-outs for Rubraca expected in 2022, with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy Phase 1/2 LuMIERE study of targeted radiotherapy candidate FAP-2286 ongoing; initial Phase 1 data expected at nuclear medicine-focused meetings in 2022, as well as initiation of Phase 2 expansion cohorts in multiple tumor types $148.8M in Rubraca® (rucaparib) global net product revenues for 2021, down 10% vs 2020; $36.0M in Rubraca global net product revenues for Q4 2021, down 5% vs Q3 2021 and 17% vs Q4 2020 Continued impact of COVID-19 on ovarian cancer diagnoses and treatments Reduction in R&D of $71.1M

Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter 2021 and year end 2021 financial results on Wednesday, February 23, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company's results in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days. Dial-in numbers for the conference call are as follows: US participants 888.440.4615, International participants 646.960.0682, conference ID: 2259685. About Clovis Oncology Clovis Oncology, Inc. is a

Estimated $35.5M - $36.1M in Rubraca® (rucaparib) global sales for Q4 2021 and $148.3M - $148.9M for FY 2021 Continuing impact on ovarian cancer diagnoses and treatments from COVID-19 Q4/FY 2021 Operating Results call planned for February 23, 2022 Company to present at J.P. Morgan Healthcare Conference on Wednesday, January 12 Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures. Unaudited preliminary results include: $35

$37.9M in Rubraca® (rucaparib) global net product revenues for Q3 2021, up 3% over Q2 2021 and down 2% from Q3 2020 Three top-line Phase 3 data read-outs for Rubraca expected in 2022 with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy Phase 1 LuMIERE study of targeted radiotherapy candidate FAP-2286 ongoing; initial Phase 1 data expected at medical meeting in 2022, as well as initiation of Phase 2 expansion cohorts in multiple tumor types Retired final $64.4M in principal amount of 2021 notes and raised net proceeds of $41.5M through ATM equity offering program in Q3 2021, complementing ongoing focus on cost control $171.9M i

Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its third quarter 2021 financial results on Wednesday, November 3, 2021, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company's results in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days. Dial-in numbers for the conference call are as follows: US participants 888.440.4615, International participants 646.960.0682, conference ID: 2259685. About Clovis Oncology Clovis Oncology, Inc. is a biopharmaceutical co

$36.8M in Rubraca® (rucaparib) global net product revenues for Q2 2021, down 8% vs. Q2 2020, due to continuing impact of COVID-19 Phase 1/2 LuMIERE clinical study of FAP-2286 open for enrollment, first peptide-targeted radionuclide therapeutic candidate targeting FAP in clinical development Three top-line Phase 3 data read-outs for Rubraca anticipated over the next six to 18 months with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy $72.5M in net proceeds raised through "at-the-market" equity offering program in Q2 2021 $230.2M in cash and cash equivalents and $48.1M in available funding under the ATHENA financing at June

Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its second quarter 2021 financial results on Wednesday, August 4, 2021, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company's results in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days. Dial-in numbers for the conference call are as follows: US participants 877.698.7048 International participants 647.689.5448, conference ID: 3887398. About Clovis Oncology Clovis Oncology, Inc. is a biopharmaceutical comp